Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors.

Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A (2012) 2.27

Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci U S A (2004) 2.14

The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol (2012) 1.70

Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Curr Opin Struct Biol (2010) 1.62

Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: progress and prognosis. Cold Spring Harb Perspect Biol (2011) 1.41

Small-molecule-mediated stabilization of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants against unfolding and aggregation. Proc Natl Acad Sci U S A (2005) 1.36

Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma. Proc Natl Acad Sci U S A (2001) 1.19

Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies. J Med Chem (2008) 1.10

Toward optimization of the second aryl substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies. J Med Chem (2009) 0.99

A stilbene that binds selectively to transthyretin in cells and remains dark until it undergoes a chemoselective reaction to create a bright blue fluorescent conjugate. J Am Chem Soc (2010) 0.92

Regioselective copper-catalyzed amination of bromobenzoic acids using aliphatic and aromatic amines. J Org Chem (2006) 0.90

A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin. Bioorg Med Chem (2010) 0.87

Iodine atoms: a new molecular feature for the design of potent transthyretin fibrillogenesis inhibitors. PLoS One (2009) 0.87

Regioselective copper-catalyzed amination of chlorobenzoic acids: synthesis and solid-state structures of N-aryl anthranilic acid derivatives. J Org Chem (2006) 0.84

Improving binding specificity of pharmacological chaperones that target mutant superoxide dismutase-1 linked to familial amyotrophic lateral sclerosis using computational methods. J Med Chem (2010) 0.83

Current and future treatment of amyloid diseases. J Intern Med (2016) 0.83

4'-Iodo-4'-deoxydoxorubicin disrupts the fibrillar structure of transthyretin amyloid. Am J Pathol (2000) 0.81

Comparative in vitro and ex vivo activities of selected inhibitors of transthyretin aggregation: relevance in drug design. Biochem J (2007) 0.80

Rigorous treatment of multispecies multimode ligand-receptor interactions in 3D-QSAR: CoMFA analysis of thyroxine analogs binding to transthyretin. J Chem Inf Model (2011) 0.77

Disaggregation of Amylin Aggregate by Novel Conformationally Restricted Aminobenzoic Acid containing α/β and α/γ Hybrid Peptidomimetics. Sci Rep (2017) 0.75

Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors. Bioorg Med Chem Lett (2017) 0.75

Amyloid diseases: abnormal protein aggregation in neurodegeneration. Proc Natl Acad Sci U S A (1999) 3.54

The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry (1996) 3.42

Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry (1992) 3.19

The folding mechanism of a beta-sheet: the WW domain. J Mol Biol (2001) 3.00

Rational design of potent human transthyretin amyloid disease inhibitors. Nat Struct Biol (2000) 2.57

Characterization of the WW domain of human yes-associated protein and its polyproline-containing ligands. J Biol Chem (1997) 2.08

Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc Natl Acad Sci U S A (1996) 1.97

Differences in age and body site distribution of the histological subtypes of basal cell carcinoma. A possible indicator of differing causes. Arch Dermatol (1997) 1.95

Protein subunit interactions and structural integrity of amyloidogenic transthyretins: evidence from electrospray mass spectrometry. J Mol Biol (1998) 1.88

Trans-suppression of misfolding in an amyloid disease. Science (2001) 1.88

Therapeutic strategies to ameliorate lysosomal storage disorders--a focus on Gaucher disease. Cell Mol Life Sci (2006) 1.86

An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured. Biochemistry (2001) 1.85

Comparative characterization of a wild type and transmembrane domain-deleted fatty acid amide hydrolase: identification of the transmembrane domain as a site for oligomerization. Biochemistry (1998) 1.80

Number of melanocytic nevi as a major risk factor for malignant melanoma. J Am Acad Dermatol (1987) 1.76

WW: An isolated three-stranded antiparallel beta-sheet domain that unfolds and refolds reversibly; evidence for a structured hydrophobic cluster in urea and GdnHCl and a disordered thermal unfolded state. Protein Sci (1999) 1.75

Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation. Biochemistry (1998) 1.72

Fine structure of fibrillar complexes associated with the basement membrane in human oral mucosa. J Cell Biol (1967) 1.66

A glimpse of a possible amyloidogenic intermediate of transthyretin. Nat Struct Biol (2000) 1.63

Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. Biochemistry (1995) 1.59

The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions. Biochemistry (1999) 1.57

Mapping the transition state of the WW domain beta-sheet. J Mol Biol (2000) 1.53

Furin initiates gelsolin familial amyloidosis in the Golgi through a defect in Ca(2+) stabilization. EMBO J (2001) 1.52

Discovering transthyretin amyloid fibril inhibitors by limited screening. Bioorg Med Chem (1998) 1.47

The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis. Proc Natl Acad Sci U S A (2001) 1.45

Titanium(IV)-mediated tandem deprotection-cyclodehydration of protected cysteine N-amides: biomimetic syntheses of thiazoline- and thiazole-containing heterocycles. Org Lett (2000) 1.44

Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug, flufenamic acid. Bioorg Med Chem (1999) 1.38

Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. Proc Natl Acad Sci U S A (1998) 1.35

Transthyretin mutation Leu-55-Pro significantly alters tetramer stability and increases amyloidogenicity. Biochemistry (1993) 1.35

Characterization of the structure and function of W --> F WW domain variants: identification of a natively unfolded protein that folds upon ligand binding. Biochemistry (1999) 1.30

Transthyretin slowly exchanges subunits under physiological conditions: A convenient chromatographic method to study subunit exchange in oligomeric proteins. Protein Sci (2001) 1.30

Neuroretinitis, aseptic meningitis, and lymphadenitis associated with Bartonella (Rochalimaea) henselae infection in immunocompetent patients and patients infected with human immunodeficiency virus type 1. Clin Infect Dis (1995) 1.29

Guanidine hydrochloride-induced denaturation and refolding of transthyretin exhibits a marked hysteresis: equilibria with high kinetic barriers. Biochemistry (1997) 1.24

Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma. Proc Natl Acad Sci U S A (2001) 1.19

Melanoma in the elderly--a neglected public health challenge. Med J Aust (1998) 1.17

Mechanisms of amyloidogenesis. Nat Struct Biol (2000) 1.17

Incorporating beta-turns and a turn mimetic out of context in loop 1 of the WW domain affords cooperatively folded beta-sheets. J Am Chem Soc (2001) 1.14

Anion shielding of electrostatic repulsions in transthyretin modulates stability and amyloidosis: insight into the chaotrope unfolding dichotomy. Biochemistry (2001) 1.10

Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: a randomized, double-blind, placebo-controlled multicenter trial. Clin Infect Dis (1998) 1.10

Progress towards understanding beta-sheet structure. Bioorg Med Chem (1996) 1.10

Recombinant human retinol-binding protein refolding, native disulfide formation, and characterization. Protein Expr Purif (1998) 1.07

Support for the multigenic hypothesis of amyloidosis: the binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity in vitro. Proc Natl Acad Sci U S A (2001) 1.06

Protofilaments, filaments, ribbons, and fibrils from peptidomimetic self-assembly:  implications for amyloid fibril formation and materials science. J Am Chem Soc (2000) 1.04

Toward smarter BCIs: extending BCIs through hybridization and intelligent control. J Neural Eng (2011) 1.03

Regression in malignant melanoma. A histologic feature without independent prognostic significance. Cancer (1985) 1.01

Increasing protein stability using a rational approach combining sequence homology and structural alignment: Stabilizing the WW domain. Protein Sci (2001) 1.01

Deuterium-proton exchange on the native wild-type transthyretin tetramer identifies the stable core of the individual subunits and indicates mobility at the subunit interface. J Mol Biol (2000) 1.00

Vitamin E and dapsone-induced hemolysis. Arch Dermatol (1984) 0.99

The amyloidogenicity of gelsolin is controlled by proteolysis and pH. Chem Biol (1999) 0.98

The nucleation of monomeric parallel beta-sheet-like structures and their self-assembly in aqueous solution. Bioorg Med Chem (1999) 0.96

The copper-mediated cross-coupling of phenylboronic acids and N-hydroxyphthalimide at room temperature: synthesis of aryloxyamines. Org Lett (2001) 0.96

Clinical diagnosis of dysplastic melanocytic nevi. A clinicopathologic correlation. J Am Acad Dermatol (1986) 0.95

Destabilization of Ca2+-free gelsolin may not be responsible for proteolysis in Familial Amyloidosis of Finnish Type. Proc Natl Acad Sci U S A (2001) 0.94

Medium-dependent self-assembly of an amphiphilic peptide: direct observation of peptide phase domains at the air-water interface. J Am Chem Soc (2001) 0.93

Gastric acid secretion in HIV-1 infection. Am J Gastroenterol (1992) 0.91

The frequency of local recurrence and microsatellites as a guide to reexcision margins for cutaneous malignant melanoma. Ann Surg (1984) 0.89

Pernio. A possible association with chronic myelomonocytic leukemia. Arch Dermatol (1985) 0.89

FAP mutations destabilize transthyretin facilitating conformational changes required for amyloid formation. Ciba Found Symp (1996) 0.88

Incidence of colonization, nosocomial pneumonia, and mortality in critically ill patients using a Trach Care closed-suction system versus an open-suction system: prospective, randomized study. Crit Care Med (1990) 0.87

Sulfated acid mucopolysaccharides in the cortical granules of eggs. Effects of quaternary ammonium salts on fertilization. Exp Cell Res (1974) 0.86

The diflunisal trial: update on study drug tolerance and disease progression. Amyloid (2011) 0.85

Improving mass spectrometric sequencing of arginine-containing peptides by derivatization with acetylacetone. J Mass Spectrom (1997) 0.85

Characteristics of familial and non-familial melanoma in Australia. Melanoma Res (1998) 0.82

Thin level IV malignant melanoma. A subset in which level is the major prognostic indicator. Ann Surg (1985) 0.81

Beta-sheet rearrangements: serpins and beyond. Protein Eng (1992) 0.81

Clinical and dermoscopic characteristics of Merkel cell carcinoma. Br J Dermatol (2013) 0.80

Peptide and protein synthesis by segment synthesis-condensation. Science (1989) 0.80

Amino acids that specify structure through hydrophobic clustering and histidine-aromatic interactions lead to biologically active peptidomimetics. Bioorg Med Chem (1994) 0.79

Serum angiotensin-converting enzyme level is elevated in patients with human immunodeficiency virus infection. Arch Intern Med (1992) 0.79

T-cell subsets with a naive phenotype are selectively decreased in the peripheral blood of patients with mycosis fungoides. J Invest Dermatol (1991) 0.79

Purification of cortical granules from unfertilized sea urchin egg homogenates by zonal centrifugation. Dev Biol (1972) 0.79

Frequency and duration of patient follow-up after treatment of a primary malignant melanoma. J Am Acad Dermatol (1985) 0.78

Retinoids to prevent skin cancer in organ transplant recipients. Lancet (1991) 0.77

Regioselective phosphoranylation and cyclodehydration of triols with diethoxytriphenylphosphorane. J Am Chem Soc (1986) 0.77

Validation of catheter semiquantitative culture technique for nonstaphylococcal organisms. J Clin Microbiol (1996) 0.77

Randomized comparison of cefepime and ceftazidime for treatment of hospitalized patients with gram-negative bacteremia. Clin Infect Dis (1995) 0.77

Scleredema of Buschke: a report of seven cases. Australas J Dermatol (1996) 0.76

Spitz naevi misdiagnosed histologically as melanoma: prevalence and clinical profile. Australas J Dermatol (1997) 0.76

The eastern Australian childhood nevus study: prevalence of atypical nevi, congenital nevus-like nevi, and other pigmented lesions. J Am Acad Dermatol (1995) 0.76

The distribution of melanocytic naevi in melanoma patients and control subjects. Australas J Dermatol (1989) 0.76

Intermolecular disulfide linkages are not required for transthyretin amyloid fibril formation in vitro. Biochem Biophys Res Commun (1993) 0.76

Primary cutaneous malignant melanoma: diagnosis and management. Aust Fam Physician (1986) 0.76

Serum interleukin-2 receptor levels and cutaneous T-cell lymphoma. Australas J Dermatol (1991) 0.76

The lack of utility of the latex agglutination test for detection of Candida antigen in the diagnosis of systemic candidiasis. Mil Med (1991) 0.76

Familial Kaposi's sarcoma and Paget's disease of bone. Australas J Dermatol (1998) 0.75

Effective treatment of cerebral toxoplasmosis with doxycycline. Am J Med (1992) 0.75

Factitious infections in orthopedic patients. Orthopedics (1993) 0.75

Lessening patient stress in the CCU. Nurs Manage (1983) 0.75

Melanocytic naevi in eastern Australia--latitude is important but most variation is within cities. Australas J Dermatol (1999) 0.75

Rifabutin-induced ageusia. Ann Intern Med (1993) 0.75

In memory of Helen Lamb Frost. CANA (1980) 0.75

Dermal cylindroma and eccrine spiradenoma. Australas J Dermatol (1996) 0.75

South Carolina florists dermatitis: case report and survey results. J S C Med Assoc (1988) 0.75

A new fluorescent method with phenanthrenequinone for the histochemical demonstration of arginine residues in tissues. J Histochem Cytochem (1969) 0.75

An international study of educational programs for nurses providing anesthesia care. AANA J (1994) 0.75

Competence and cost of educational models. AANA J (1988) 0.75

The case for teaching history to student nurse anesthetists. AANA J (2001) 0.75